STAT Plus: Novartis data set up multibillion-dollar battle over breast cancer drugs
The success of the trial of Kisqali, a CDK 4/6 inhibitor, could set up one of the biggest marketing battles in cancer.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
STAT Plus: Bernie Sanders’ accidentally great drug pricing idea
STAT Plus: Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS
STAT Plus: With arrival of breakthrough therapies, a rare disease group reconsiders the possible — and its mission
STAT Plus: Strengthen science by funding living evidence synthesis
Opinion
STAT Plus: The conundrum of biopharma investing: low rewards and high risks — but a big social benefit
Risk-reward parity says expected returns on investments should be commensurate with the risks. That's not the case for biopharma investing.
Read The Story
Video
STAT Plus: Watch: An interview with the FDA’s top cancer regulator
Rich Pazdur, the director of the FDA Oncology Center of Excellence, addressed rapid approvals, diversity in clinical trials, and more.
Read The Story
All Coverage
advertisement
